372 related articles for article (PubMed ID: 25260373)
1. Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials.
Berhan A; Barker A
BMC Psychiatry; 2014 Sep; 14():276. PubMed ID: 25260373
[TBL] [Abstract][Full Text] [Related]
2. Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder.
Pae CU; Wang SM; Han C; Lee SJ; Patkar AA; Masand PS; Serretti A
J Psychiatry Neurosci; 2015 May; 40(3):174-86. PubMed ID: 25350320
[TBL] [Abstract][Full Text] [Related]
3. Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials.
Li G; Wang X; Ma D
Clin Drug Investig; 2016 Jul; 36(7):509-17. PubMed ID: 27067232
[TBL] [Abstract][Full Text] [Related]
4. Vortioxetine for the treatment of depression.
Pearce EF; Murphy JA
Ann Pharmacother; 2014 Jun; 48(6):758-65. PubMed ID: 24676550
[TBL] [Abstract][Full Text] [Related]
5. The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis.
Meeker AS; Herink MC; Haxby DG; Hartung DM
Syst Rev; 2015 Mar; 4():21. PubMed ID: 25874839
[TBL] [Abstract][Full Text] [Related]
6. [Vortioxetine in the treatment of major depression].
de Bartolomeis A; Fagiolini A; Maina G
Riv Psichiatr; 2016; 51(6):215-230. PubMed ID: 27996982
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD.
Mahableshwarkar AR; Jacobsen PL; Chen Y; Serenko M; Trivedi MH
Psychopharmacology (Berl); 2015 Jun; 232(12):2061-70. PubMed ID: 25575488
[TBL] [Abstract][Full Text] [Related]
8. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine.
Montgomery SA; Nielsen RZ; Poulsen LH; Häggström L
Hum Psychopharmacol; 2014 Sep; 29(5):470-82. PubMed ID: 25087600
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of 5 mg/d Vortioxetine compared to placebo for major depressive disorder: A meta-analysis.
Fu J; Chen Y
Psychopharmacology (Berl); 2015 Jan; 232(1):7-16. PubMed ID: 24871704
[TBL] [Abstract][Full Text] [Related]
10. A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms.
Baldwin DS; Florea I; Jacobsen PL; Zhong W; Nomikos GG
J Affect Disord; 2016 Dec; 206():140-150. PubMed ID: 27474960
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients aged 55 years or older.
Nomikos GG; Tomori D; Zhong W; Affinito J; Palo W
CNS Spectr; 2017 Aug; 22(4):348-362. PubMed ID: 27869048
[TBL] [Abstract][Full Text] [Related]
12. A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults.
Thase ME; Mahableshwarkar AR; Dragheim M; Loft H; Vieta E
Eur Neuropsychopharmacol; 2016 Jun; 26(6):979-93. PubMed ID: 27139079
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
Mahableshwarkar AR; Jacobsen PL; Chen Y
Curr Med Res Opin; 2013 Mar; 29(3):217-26. PubMed ID: 23252878
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of different doses of three new antidepressants for treating major depressive disorder: A PRISMA-compliant meta-analysis.
He H; Wang W; Lyu J; Zheng J; Guo L; An X; Fan Y; Ma X
J Psychiatr Res; 2018 Jan; 96():247-259. PubMed ID: 29127931
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder.
Boulenger JP; Loft H; Olsen CK
Int Clin Psychopharmacol; 2014 May; 29(3):138-49. PubMed ID: 24257717
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
Jain R; Mahableshwarkar AR; Jacobsen PL; Chen Y; Thase ME
Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder.
Mahableshwarkar AR; Jacobsen PL; Serenko M; Chen Y; Trivedi MH
J Clin Psychiatry; 2015 May; 76(5):583-91. PubMed ID: 26035186
[TBL] [Abstract][Full Text] [Related]
18. Vortioxetine: a New Treatment for Major Depressive Disorder.
Connolly KR; Thase ME
Expert Opin Pharmacother; 2016; 17(3):421-31. PubMed ID: 26679430
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder.
Jacobsen PL; Mahableshwarkar AR; Serenko M; Chan S; Trivedi MH
J Clin Psychiatry; 2015 May; 76(5):575-82. PubMed ID: 26035185
[TBL] [Abstract][Full Text] [Related]
20. Vortioxetine: a review of its use in major depressive disorder.
Garnock-Jones KP
CNS Drugs; 2014 Sep; 28(9):855-74. PubMed ID: 25145538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
